VRTOG 2018 Meeting Minutes

ACVR 2018 Fort Worth, TX
VCS 2018 Louisville, KY

VRTOG business meeting 7 am

Attendance: Tracy Gieger, Valerie Poirier, Molly Holmes, Nick Rancilio, Miriam Kleiter, Michelle Turek, Carlie Maitz, Jayme Looper, Valerie Porier, Isabella Vanhaezebrouck, Katie Swift, Keara Boss, Pamela White, Lisa DiBernardi, Jeannie Plantenza, Jenny Schutte, Nate VanAssclt, John Farrelly, Joe Jacovino, Stephanie Cook, Valeria Heier, Carla Rohubach, Michael Kent, Sue LaRue, Rachel St. Vincent, Glen King

- VRTOG Minutes from 2017 approved
- Review of leadership of VRTOG
- New dues process coming in 2019—may be linked with paying ACVR dues
- Treasury report
- Clinical Studies review
- Zoetis Funds—$40,000
  - Open call for proposals
  - Contact Nathan Lee or Ira Gordon if interested
- Call for nominations
  - Associate Chair (1)
  - Dr. Nick Rancilio volunteered and was confirmed by majority vote
  - Member at large (1)
  - Dr. Jenny Schutte volunteered and was confirmed by majority vote
- Funded Keynote speaker
  - 2018 IVRA/ACVR meeting in TX
- VRTOG-AAPM Group- Steve Saparetto
  - Group of medical physicists that work to support the VRTOG
  - Current trends in human medicine making human fractionation protocols (SRT) more similar to ways that animals have been treated
  - WGVRTO(G)—working group
  - Survey of veterinary hospitals with radiation capabilities—working to define what is available and how units are used
  - Work to improve and/or standardize QA + provide support
  - Grant preparation and funding assistance
  - Recognize difference in veterinary RO (different sized phantoms needed)- may utilize 3D printing
  - Center for Innovation in RO (CIRO)- https://www.nrgoncology.org/Scientific-Program/Center-for-Innovation-in-Radiation-Oncology
  - Discussion on capabilities of 3D printing and current limitations
- Discussion:
  - Discussion RE: VRTOG funds- discussion about funding resident grants for travel vs. research. The point was reiterated that VRTOG funds were available to help with statistical support or other scientific support that might not be available at the
institution conducting the trial. It was suggested that using general funds to fund studies might necessitate a dues increase.